<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03101267</url>
  </required_header>
  <id_info>
    <org_study_id>4070-CL-0020</org_study_id>
    <nct_id>NCT03101267</nct_id>
  </id_info>
  <brief_title>A Dose-finding Study of ASP4070</brief_title>
  <official_title>Phase 2 Dose-finding Study of ASP4070 - A Randomized, Double-blind, Placebo-controlled, Dose-finding Study in Patients With Cedar Pollinosis Using an Environmental Exposure Chamber -</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Astellas Pharma Inc</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Immunomic Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Astellas Pharma Inc</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study was to evaluate the efficacy, safety, and dose-response of
      ASP4070 vaccinated in patients with cedar pollinosis.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Subjects were vaccinated with ASP4070 or placebo at 2 week intervals. Clinical symptoms were
      evaluated after cedar pollen exposure in a chamber at 4, 8 and 12 weeks after the last
      vaccination to identify the timing of the onset of therapeutic effect.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">April 13, 2017</start_date>
  <completion_date type="Actual">October 27, 2018</completion_date>
  <primary_completion_date type="Actual">January 26, 2018</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change From Pre-Exposure in Mean Total 3 Nasal Symptom Score (3TNSS) 120 to 180 Minutes After Start of Cedar Pollen Exposure on Day 183</measure>
    <time_frame>Day 183 at pre-exposure and 120 to 180 minutes after the start of cedar pollen exposure (5 samples 15 minutes apart)</time_frame>
    <description>Participants were assessed for each symptom (sneezing, nasal discharge and nasal congestion) using the following score every 15 minutes from before cedar pollen exposure until 180 minutes after cedar pollen exposure.
0: None (no symptoms)
Mild (symptoms present but easily tolerated)
Moderate (awareness of symptoms; bothersome, but tolerable)
Severe (definite awareness of symptoms; difficult to tolerate, but does not interfere with the activities of daily living)
Very severe (difficult to tolerate and interferes with the activities of daily living).
3TNSS was a summed score of each symptom, and mean of 3TNSS at 120 to 180 min is the average of 5 timepoints of 3TNSS score, which ranged from 0 to 12. Higher 3TNSS score indicated greater disease activity.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change From Pre-Exposure in Mean Total 4 Nasal Symptom Score (4TNSS) 120 to 180 Minutes After Cedar Pollen Exposure</measure>
    <time_frame>Pre-exposure and 120-180 minutes after the start of pollen exposure (5 samples 15 minutes apart) on Days 127, 155, and 183</time_frame>
    <description>Participants were assessed for each symptom (sneezing, nasal discharge, nasal congestion and itchy nose) using the following score every 15 minutes from before cedar pollen exposure until 180 minutes after cedar pollen exposure.
0: None (no symptoms)
Mild (symptoms present but easily tolerated)
Moderate (awareness of symptoms; bothersome, but tolerable)
Severe (definite awareness of symptoms; difficult to tolerate, but did not interfere with the activities of daily living)
Very severe (difficult to tolerate and interfered with the activities of daily living). 4TNSS was a summed score of each symptom, and mean of 4TNSS at 120 to 180 min is the average of 5 timepoints of 4TNSS score, which ranged from 0 to 16. Higher 4TNSS score indicated greater disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Pre-Exposure in Sneezing Score 120 to 180 Minutes After Cedar Pollen Exposure</measure>
    <time_frame>Pre-exposure and 120-180 minutes after the start of pollen exposure (5 samples 15 minutes apart) on Days 127, 155, and 183</time_frame>
    <description>Participants were assessed for sneezing using the following score every 15 minutes from before cedar pollen exposure until 180 minutes after cedar pollen exposure. The mean of score at 120 to 180 minutes was calculated.
0: None (no symptoms)
Mild (symptoms present but easily tolerated)
Moderate (awareness of symptoms; bothersome, but tolerable)
Severe (definite awareness of symptoms; difficult to tolerate, but did not interfere with the activities of daily living)
Very severe (difficult to tolerate and interfered with the activities of daily living)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Pre-Exposure in Nasal Discharge Score 120 to 180 Minutes After Cedar Pollen Exposure</measure>
    <time_frame>Pre-exposure and 120-180 minutes after the start of pollen exposure (5 samples 15 minutes apart) on Days 127, 155, and 183</time_frame>
    <description>Participants were assessed for nasal discharge using the following score every 15 minutes from before cedar pollen exposure until 180 minutes after cedar pollen exposure. The mean of score at 120 to 180 minutes was calculated.
0: None (no symptoms)
Mild (symptoms present but easily tolerated)
Moderate (awareness of symptoms; bothersome, but tolerable)
Severe (definite awareness of symptoms; difficult to tolerate, but did not interfere with the activities of daily living)
Very severe (difficult to tolerate and interfered with the activities of daily living)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Pre-Exposure in Mean Nasal Congestion Score 120 to 180 Minutes After Cedar Pollen Exposure</measure>
    <time_frame>Pre-exposure and 120-180 minutes after the start of pollen exposure (5 samples 15 minutes apart) on Days 127, 155, and 183</time_frame>
    <description>Participants were assessed for nasal congestion using the following score every 15 minutes from before cedar pollen exposure until 180 minutes after cedar pollen exposure. The mean of score at 120 to 180 minutes was calculated.
0: None (no symptoms)
Mild (symptoms present but easily tolerated)
Moderate (awareness of symptoms; bothersome, but tolerable)
Severe (definite awareness of symptoms; difficult to tolerate, but did not interfere with the activities of daily living)
Very severe (difficult to tolerate and interfered with the activities of daily living)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Pre-Exposure in Mean Itchy Nose Score 120 to 180 Minutes After Cedar Pollen Exposure</measure>
    <time_frame>Pre-exposure and 120-180 minutes after the start of pollen exposure (5 samples 15 minutes apart) on Days 127, 155, and 183</time_frame>
    <description>Participants were assessed for itchy nose using the following score every 15 minutes from before cedar pollen exposure until 180 minutes after cedar pollen exposure. The mean of score at 120 to 180 minutes was calculated.
0: None (no symptoms)
Mild (symptoms present but easily tolerated)
Moderate (awareness of symptoms; bothersome, but tolerable)
Severe (definite awareness of symptoms; difficult to tolerate, but did not interfere with the activities of daily living)
Very severe (difficult to tolerate and interfered with the activities of daily living)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Pre-Exposure in Mean Total Non-Nasal Symptom Score (TNNSS) 120 to 180 Minutes After Cedar Pollen Exposure</measure>
    <time_frame>Pre-exposure and 120-180 minutes after the start of pollen exposure (5 samples 15 minutes apart) on Days 127, 155, and 183</time_frame>
    <description>Participants were assessed for each non-nasal symptom (itchy eyes and watery eyes) using the following score every 15 minutes from before cedar pollen exposure until 180 minutes after cedar pollen exposure.
0: None (no symptoms)
Mild (symptoms present but easily tolerated)
Moderate (awareness of symptoms; bothersome, but tolerable)
Severe (definite awareness of symptoms; difficult to tolerate, but did not interfere with the activities of daily living)
Very severe (difficult to tolerate and interfered with the activities of daily living).
TNNSS was a summed score of each symptom, and mean of TNNSS at 120 to 180 min is the average of 5 timepoints of TNNSS score, which ranged from 0 to 8. Higher TNNSS score indicated greater disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Pre-Exposure in Mean Itchy Eyes Score 120 to 180 Minutes After Cedar Pollen Exposure</measure>
    <time_frame>Pre-exposure and 120-180 minutes after the start of pollen exposure (5 samples 15 minutes apart) on Days 127, 155, and 183</time_frame>
    <description>Participants were assessed for itchy eyes using the following score every 15 minutes from before cedar pollen exposure until 180 minutes after cedar pollen exposure. The mean of score at 120 to 180 minutes was calculated.
0: None (no symptoms)
Mild (symptoms present but easily tolerated)
Moderate (awareness of symptoms; bothersome, but tolerable)
Severe (definite awareness of symptoms; difficult to tolerate, but did not interfere with the activities of daily living)
Very severe (difficult to tolerate and interfered with the activities of daily living)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Pre-Exposure in Mean Watery Eyes Score 120 to 180 Minutes After Cedar Pollen Exposure</measure>
    <time_frame>Pre-exposure and 120-180 minutes after the start of pollen exposure (5 samples 15 minutes apart) on Days 127, 155, and 183</time_frame>
    <description>Participants were assessed for watery eyes using the following score every 15 minutes from before cedar pollen exposure until 180 minutes after cedar pollen exposure. The mean of score at 120 to 180 minutes was calculated.
0: None (no symptoms)
Mild (symptoms present but easily tolerated)
Moderate (awareness of symptoms; bothersome, but tolerable)
Severe (definite awareness of symptoms; difficult to tolerate, but did not interfere with the activities of daily living)
Very severe (difficult to tolerate and interfered with the activities of daily living)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Pre-Exposure in Total 5 Symptom Score (5TSS) 120 to 180 Minutes After Cedar Pollen Exposure</measure>
    <time_frame>Pre-exposure and 120-180 minutes after the start of pollen exposure (5 samples 15 minutes apart) on Days 127, 155, and 183</time_frame>
    <description>Participants were assessed for each 5TSS (sneezing, nasal discharge, nasal congestion, itchy eyes and watery eyes) using the following score every 15 minutes from before cedar pollen exposure until 180 minutes after cedar pollen exposure.
0: None (no symptoms)
Mild (symptoms present but easily tolerated)
Moderate (awareness of symptoms; bothersome, but tolerable)
Severe (definite awareness of symptoms; difficult to tolerate, but did not interfere with the activities of daily living)
Very severe (difficult to tolerate and interfered with the activities of daily living).
5TSS was a summed score of each symptom, and mean of 5TSS at 120 to 180 min is the average of 5 timepoints of 5TSS score, which ranged from 0 to 20. Higher 5TSS score indicated greater disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change From Pre-Exposure in Mean Total 6 Symptom Score (6TSS) 120 to 180 Minutes After Cedar Pollen Exposure</measure>
    <time_frame>Pre-exposure and 120-180 minutes after the start of pollen exposure (5 samples 15 minutes apart) on Days 127, 155, and 183</time_frame>
    <description>Participants were assessed for each 6TSS (sneezing, nasal discharge, nasal congestion, itchy nose, itchy eyes and watery eyes) using the following score every 15 minutes from before cedar pollen exposure until 180 minutes after cedar pollen exposure.
0: None (no symptoms)
Mild (symptoms present but easily tolerated)
Moderate (awareness of symptoms; bothersome, but tolerable)
Severe (definite awareness of symptoms; difficult to tolerate, but did not interfere with the activities of daily living)
Very severe (difficult to tolerate and interfered with the activities of daily living).
6TSS was a summed score of each symptom, and mean of 6TSS at 120 to 180 min is the average of 5 timepoints of 6TSS score, which ranged from 0 to 24. Higher 6TSS score indicated greater disease activity.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Occurrence of Nasal or Eye Symptom From Start of Cedar Pollen Exposure</measure>
    <time_frame>Days 127, 155 and 183, from the start of cedar pollen exposure for up to 180 minutes</time_frame>
    <description>Time point when the score of nasal or eye symptom worsens by 1 or more as compared to before cedar pollen exposure were assessed.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Amount of Nasal Discharge Per 30 Minutes During Cedar Pollen Exposure</measure>
    <time_frame>Day 127: 0-30 min, 30-60 min, 60-90 min, 90-120 min, 120-150 min, 150-180 min, Day 155: 0-30 min, 30-60 min, 60-90 min, 90-120 min, 120-150 min, 150-180 min, Day 183: 0-30 min, 30-60 min, 60-90 min, 90-120 min, 120-150 min, 150-180 min</time_frame>
    <description>Nasal discharge amount was calculated by the difference in the weight of the tissue paper before and after use by participants who were instructed to use pre-allocated tissues for blowing their nose.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Sneezing Count Per 30 Minutes During Cedar Pollen Exposure</measure>
    <time_frame>Day 127: 0-30 min, 30-60 min, 60-90 min, 90-120 min, 120-150 min, 150-180 min, Day 155: 0-30 min, 30-60 min, 60-90 min, 90-120 min, 120-150 min, 150-180 min, Day 183: 0-30 min, 30-60 min, 60-90 min, 90-120 min, 120-150 min, 150-180 min</time_frame>
    <description>Sneezing count per 30 minutes were measured during chamber exposure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Adverse Events (AE) During the Primary Study Period</measure>
    <time_frame>From first dose of study drug up to the end of primary study period (up to 7 days after Day 183)</time_frame>
    <description>Treatment emergent adverse events (TEAE) was defined as an AE observed after starting administration of the test drug/comparative drug. A drug-related TEAE was a TEAE with either possible or probable relationship to the study drug as assessed by the investigator. Severity of AEs was assessed according to the following 4 levels. Mild: no disruption of normal daily activities, Moderate: affect normal daily activities, Severe: inability to perform daily activities, Life-threatening: necessity for urgent intervention.
If the investigator or subinvestigator examined the patient and determined that the following items occurred from the date of study drug vaccination until 14 days after vaccination and a relationship with the study drug could not be negated, then it was evaluated as a local/systemic reaction at the vaccination site.
Local reactions: pain, tenderness, erythema/redness and induration/swelling
Systemic reactions: nausea/vomiting, diarrhea, headache, fatigue and myalgia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With Serious Adverse Events (SAE) During the Long-Term Safety Follow-Up Period</measure>
    <time_frame>Up to 9 months after the end of primary study period (primary study period was up to 7 days after Day 183)</time_frame>
    <description>If SAEs occurred, then the participant was to contact the study site. With regard to participants who had discontinued the study during the primary study period, if the study drug had been vaccinated even once, then safety information (SAEs) was collected for 1 year after the final vaccination.</description>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">150</enrollment>
  <condition>Rhinitis, Allergic, Seasonal</condition>
  <arm_group>
    <arm_group_label>ASP4070 4 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received ASP4070 4 mg 8 times by intradermal vaccination at 14-day intervals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ASP4070 1 mg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants received ASP4070 1 mg 8 times by intradermal vaccination at 14-day intervals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants received Placebo 8 times by intradermal vaccination at 14-day intervals.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ASP4070</intervention_name>
    <description>Intradermal vaccination at 2-week intervals</description>
    <arm_group_label>ASP4070 1 mg</arm_group_label>
    <arm_group_label>ASP4070 4 mg</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Intradermal vaccination at 2-week intervals</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Subject who has exhibited symptoms of cedar pollinosis, consisting of nasal symptoms
             (sneezing, nasal discharge or nasal obstruction) and eye symptoms (itchy eyes or
             watery eyes) during the pollen dispersal seasons in 2016 and 2017

          -  Subject who is positive for the Japanese red cedar (JRC) pollen-specific serum IgE
             antibody test

          -  At screening, subject whose score has worsened compared to baseline over 120 to 180
             minutes after cedar pollen exposure in a chamber

        Exclusion Criteria:

          -  Subject who has positive the test result of serum IgE antibody specific to other
             antigen than JRC pollen at screening

          -  Subject who has received specific immunotherapy (including desensitization therapy)
             for cedar pollinosis in the past

          -  Subject who has received specific or non-specific immunotherapy within 5 years prior
             to screening

          -  Subject who has received laser therapy or surgery for the treatment of nasal symptoms
             within 3 years prior to screening.

          -  Subject who has a history of allergic reactions such as anaphylactic shock and
             exanthema generalized caused by food and/or medical products in the past

          -  Subject who has a positive test result for hepatitis B surface (HBs) antigen or
             anti-hepatitis C virus (HCV) antibody

          -  Subject who has nasal disease that may interfere with the evaluation

          -  Subject who has autoimmune disease or other serious primary disease

          -  Subject who was diagnosed with immunodeficiency in the past

          -  Subject who has a complication of seasonal allergic rhinitis (due to allergens other
             than Japanese cedars or cypress), perennial allergic rhinitis, rhinitis medicamentosa,
             or non-allergic rhinitis that requires medical treatment

          -  Subject who has a complication of cardiovascular disease

          -  Subject who has a complication of hepatic disease

          -  Subject who has a complication of renal disease

          -  Subject who has a complication of respiratory disease

          -  Subject has a complication of malignant tumor or has been diagnosed with or has
             received treatment for malignant tumor within 5 years prior to the first vaccination
             of the study drug

          -  Subject who was diagnosed with schizophrenia, other mental conditions

          -  Subject who has a complication that may have an impact on the results of the local or
             systemic reaction

          -  Subject who has received a vaccination of Cry j 2-LAMP vaccine

          -  Subject who has participated in a clinical study of ASP4070 and received a vaccination
             of the study drug.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Astellas Pharma Inc</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Site JP00001</name>
      <address>
        <city>Shinjuku</city>
        <state>Tokyo</state>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>https://astellasclinicalstudyresults.com/hcp/study.aspx?ID=361</url>
    <description>Link to results on the Astellas Clinical Study Results website</description>
  </link>
  <verification_date>May 2020</verification_date>
  <study_first_submitted>April 2, 2017</study_first_submitted>
  <study_first_submitted_qc>April 2, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 5, 2017</study_first_posted>
  <results_first_submitted>May 10, 2020</results_first_submitted>
  <results_first_submitted_qc>May 10, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">June 4, 2020</results_first_posted>
  <disposition_first_submitted>January 4, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>January 4, 2019</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">January 7, 2019</disposition_first_posted>
  <last_update_submitted>June 16, 2020</last_update_submitted>
  <last_update_submitted_qc>June 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Cedar pollinosis</keyword>
  <keyword>ASP4070</keyword>
  <keyword>DNA plasmid vaccine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rhinitis</mesh_term>
    <mesh_term>Rhinitis, Allergic</mesh_term>
    <mesh_term>Rhinitis, Allergic, Seasonal</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Access to anonymized individual participant level data collected during the study, in addition to study-related supporting documentation, is planned for studies conducted with approved product indications and formulations, as well as compounds terminated during development. Studies conducted with product indications or formulations that remain active in development are assessed after study completion to determine if Individual Participant Data can be shared. Conditions and exceptions are described under the Sponsor Specific Details for Astellas on www.clinicalstudydatarequest.com.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>Access to participant level data is offered to researchers after publication of the primary manuscript (if applicable) and is available as long as Astellas has legal authority to provide the data.</ipd_time_frame>
    <ipd_access_criteria>Researchers must submit a proposal to conduct a scientifically relevant analysis of the study data. The research proposal is reviewed by an Independent Research Panel. If the proposal is approved, access to the study data is provided in a secure data sharing environment after receipt of a signed Data Sharing Agreement.</ipd_access_criteria>
    <ipd_url>https://www.clinicalstudydatarequest.com/</ipd_url>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 9, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT03101267/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>June 22, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/67/NCT03101267/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 150 participants with cedar pollinosis were enrolled in this study. Participants were randomly allocated to 3 groups in a ratio of 1:1:1 to ASP4070 4 mg group, ASP4070 1 mg group or placebo group.</recruitment_details>
      <pre_assignment_details>“Class of Japanese Red Cedar (JRC) pollen-specific Immunoglobulin E (IgE) antibody test at screening visit 1” and “Change from pre-exposure in mean total 3 nasal symptom (sneezing, nasal discharge and nasal congestion) score 120 to 180 minutes after start of cedar pollen exposure at screening visit 2” were used as stratification.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>ASP4070 4 mg</title>
          <description>Participants received ASP4070 4 mg 8 times by intradermal vaccination at 14-day intervals.</description>
        </group>
        <group group_id="P2">
          <title>ASP4070 1 mg</title>
          <description>Participants received ASP4070 1 mg 8 times by intradermal vaccination at 14-day intervals.</description>
        </group>
        <group group_id="P3">
          <title>Placebo</title>
          <description>Participants received Placebo 8 times by intradermal vaccination at 14-day intervals.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Primary Study Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="3"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="2"/>
                <participants group_id="P3" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Miscellaneous</title>
              <participants_list>
                <participants group_id="P1" count="2"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
        <period>
          <title>Pollinosis Symptoms Survey Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="47"/>
                <participants group_id="P2" count="48"/>
                <participants group_id="P3" count="47"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
                <participants group_id="P3" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Safety Analysis Set (SAF) consisted of all participants who were vaccinated with the study drug at least once.</population>
      <group_list>
        <group group_id="B1">
          <title>ASP4070 4 mg</title>
          <description>Participants received ASP4070 4 mg 8 times by intradermal vaccination at 14-day intervals.</description>
        </group>
        <group group_id="B2">
          <title>ASP4070 1 mg</title>
          <description>Participants received ASP4070 1 mg 8 times by intradermal vaccination at 14-day intervals.</description>
        </group>
        <group group_id="B3">
          <title>Placebo</title>
          <description>Participants received Placebo 8 times by intradermal vaccination at 14-day intervals.</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="50"/>
            <count group_id="B4" value="150"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>year</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="50"/>
                    <count group_id="B4" value="150"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="38.4" spread="8.6"/>
                    <measurement group_id="B2" value="38.1" spread="8.5"/>
                    <measurement group_id="B3" value="37.8" spread="9.3"/>
                    <measurement group_id="B4" value="38.1" spread="8.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="50"/>
                    <count group_id="B4" value="150"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="31"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="90"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="17"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="50"/>
                    <count group_id="B4" value="150"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="150"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="50"/>
                    <count group_id="B2" value="50"/>
                    <count group_id="B3" value="50"/>
                    <count group_id="B4" value="150"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="50"/>
                    <measurement group_id="B4" value="150"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Class of Japanese Red Cedar (JRC) Specific Immunoglobulin E (IgE) Antibody Test</title>
          <description>JRC specific IgE antibody test at screening visit 1 was showed. JRC specific IgE antibody was classified from Class 1 to Class 6. Participants with Class 1 and 2 was excluded in the enrollment.</description>
          <population>Full Analysis Set (FAS) consisted of all participants who were randomized, were vaccinated with the study drug at least once, and had at least 1 measurement for efficacy evaluation obtained after vaccination of the study drug.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="48"/>
                    <count group_id="B2" value="49"/>
                    <count group_id="B3" value="48"/>
                    <count group_id="B4" value="145"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>3</title>
                  <measurement_list>
                    <measurement group_id="B1" value="26"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="78"/>
                  </measurement_list>
                </category>
                <category>
                  <title>4</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="15"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>5</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="13"/>
                  </measurement_list>
                </category>
                <category>
                  <title>6</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Change From Pre-exposure in Mean of Total 3 Nasal Symptom Score During 120 to 180 Minutes</title>
          <description>At screening visit 2, participants were assessed for each symptom (sneezing, nasal discharge and nasal congestion) using the score from 0 (None; no symptoms) to 4 (Very severe) every 15 minutes from before cedar pollen exposure until 180 minutes after cedar pollen exposure. 3TNSS was a summed score of each symptom, and mean of 3TNSS at 120 to 180 min is the average of 5 timepoints of 3TNSS score, which ranged from 0 to 12. Higher 3TNSS score indicated greater disease activity.</description>
          <population>FAS</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="48"/>
                    <count group_id="B2" value="49"/>
                    <count group_id="B3" value="48"/>
                    <count group_id="B4" value="145"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="4.79" spread="1.53"/>
                    <measurement group_id="B2" value="4.89" spread="1.31"/>
                    <measurement group_id="B3" value="4.78" spread="1.25"/>
                    <measurement group_id="B4" value="4.82" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change From Pre-Exposure in Mean Total 3 Nasal Symptom Score (3TNSS) 120 to 180 Minutes After Start of Cedar Pollen Exposure on Day 183</title>
        <description>Participants were assessed for each symptom (sneezing, nasal discharge and nasal congestion) using the following score every 15 minutes from before cedar pollen exposure until 180 minutes after cedar pollen exposure.
0: None (no symptoms)
Mild (symptoms present but easily tolerated)
Moderate (awareness of symptoms; bothersome, but tolerable)
Severe (definite awareness of symptoms; difficult to tolerate, but does not interfere with the activities of daily living)
Very severe (difficult to tolerate and interferes with the activities of daily living).
3TNSS was a summed score of each symptom, and mean of 3TNSS at 120 to 180 min is the average of 5 timepoints of 3TNSS score, which ranged from 0 to 12. Higher 3TNSS score indicated greater disease activity.</description>
        <time_frame>Day 183 at pre-exposure and 120 to 180 minutes after the start of cedar pollen exposure (5 samples 15 minutes apart)</time_frame>
        <population>Full Analysis Set (FAS) consisted of all participants who were randomized, vaccinated with the study drug at least once, and had at least 1 measurement for efficacy evaluation obtained after vaccination of the study drug.</population>
        <group_list>
          <group group_id="O1">
            <title>ASP4070 4 mg</title>
            <description>Participants received ASP4070 4 mg 8 times by intradermal vaccination at 14-day intervals.</description>
          </group>
          <group group_id="O2">
            <title>ASP4070 1 mg</title>
            <description>Participants received ASP4070 1 mg 8 times by intradermal vaccination at 14-day intervals.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received Placebo 8 times by intradermal vaccination at 14-day intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Pre-Exposure in Mean Total 3 Nasal Symptom Score (3TNSS) 120 to 180 Minutes After Start of Cedar Pollen Exposure on Day 183</title>
          <description>Participants were assessed for each symptom (sneezing, nasal discharge and nasal congestion) using the following score every 15 minutes from before cedar pollen exposure until 180 minutes after cedar pollen exposure.
0: None (no symptoms)
Mild (symptoms present but easily tolerated)
Moderate (awareness of symptoms; bothersome, but tolerable)
Severe (definite awareness of symptoms; difficult to tolerate, but does not interfere with the activities of daily living)
Very severe (difficult to tolerate and interferes with the activities of daily living).
3TNSS was a summed score of each symptom, and mean of 3TNSS at 120 to 180 min is the average of 5 timepoints of 3TNSS score, which ranged from 0 to 12. Higher 3TNSS score indicated greater disease activity.</description>
          <population>Full Analysis Set (FAS) consisted of all participants who were randomized, vaccinated with the study drug at least once, and had at least 1 measurement for efficacy evaluation obtained after vaccination of the study drug.</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.04" spread="1.30"/>
                    <measurement group_id="O2" value="1.91" spread="1.82"/>
                    <measurement group_id="O3" value="1.98" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>3TNSS treatment comparison</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.777</p_value>
            <method>Mixed model for repeated measures (MMRM)</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.52</ci_lower_limit>
            <ci_upper_limit>0.69</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>3TNSS treatment comparison</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.983</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.01</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.61</ci_lower_limit>
            <ci_upper_limit>0.59</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Pre-Exposure in Mean Total 4 Nasal Symptom Score (4TNSS) 120 to 180 Minutes After Cedar Pollen Exposure</title>
        <description>Participants were assessed for each symptom (sneezing, nasal discharge, nasal congestion and itchy nose) using the following score every 15 minutes from before cedar pollen exposure until 180 minutes after cedar pollen exposure.
0: None (no symptoms)
Mild (symptoms present but easily tolerated)
Moderate (awareness of symptoms; bothersome, but tolerable)
Severe (definite awareness of symptoms; difficult to tolerate, but did not interfere with the activities of daily living)
Very severe (difficult to tolerate and interfered with the activities of daily living). 4TNSS was a summed score of each symptom, and mean of 4TNSS at 120 to 180 min is the average of 5 timepoints of 4TNSS score, which ranged from 0 to 16. Higher 4TNSS score indicated greater disease activity.</description>
        <time_frame>Pre-exposure and 120-180 minutes after the start of pollen exposure (5 samples 15 minutes apart) on Days 127, 155, and 183</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>ASP4070 4 mg</title>
            <description>Participants received ASP4070 4 mg 8 times by intradermal vaccination at 14-day intervals.</description>
          </group>
          <group group_id="O2">
            <title>ASP4070 1 mg</title>
            <description>Participants received ASP4070 1 mg 8 times by intradermal vaccination at 14-day intervals.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received Placebo 8 times by intradermal vaccination at 14-day intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Pre-Exposure in Mean Total 4 Nasal Symptom Score (4TNSS) 120 to 180 Minutes After Cedar Pollen Exposure</title>
          <description>Participants were assessed for each symptom (sneezing, nasal discharge, nasal congestion and itchy nose) using the following score every 15 minutes from before cedar pollen exposure until 180 minutes after cedar pollen exposure.
0: None (no symptoms)
Mild (symptoms present but easily tolerated)
Moderate (awareness of symptoms; bothersome, but tolerable)
Severe (definite awareness of symptoms; difficult to tolerate, but did not interfere with the activities of daily living)
Very severe (difficult to tolerate and interfered with the activities of daily living). 4TNSS was a summed score of each symptom, and mean of 4TNSS at 120 to 180 min is the average of 5 timepoints of 4TNSS score, which ranged from 0 to 16. Higher 4TNSS score indicated greater disease activity.</description>
          <population>FAS</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 127</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.21" spread="1.73"/>
                    <measurement group_id="O2" value="4.07" spread="2.69"/>
                    <measurement group_id="O3" value="4.02" spread="2.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 155</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.46" spread="2.09"/>
                    <measurement group_id="O2" value="3.20" spread="2.73"/>
                    <measurement group_id="O3" value="3.32" spread="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 183</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.71" spread="1.61"/>
                    <measurement group_id="O2" value="2.58" spread="2.50"/>
                    <measurement group_id="O3" value="2.62" spread="1.81"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>4TNSS treatment comparison at day 127</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.710</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.75</ci_lower_limit>
            <ci_upper_limit>1.10</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>4TNSS treatment comparison at day 127</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.872</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.84</ci_lower_limit>
            <ci_upper_limit>0.99</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>4TNSS treatment comparison at day 155</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.701</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.73</ci_lower_limit>
            <ci_upper_limit>1.08</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>4TNSS treatment comparison at day 155</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.925</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.95</ci_lower_limit>
            <ci_upper_limit>0.86</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>4TNSS treatment comparison at day 183</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.690</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.64</ci_lower_limit>
            <ci_upper_limit>0.97</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>4TNSS treatment comparison at day 183</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.868</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.73</ci_lower_limit>
            <ci_upper_limit>0.87</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Pre-Exposure in Sneezing Score 120 to 180 Minutes After Cedar Pollen Exposure</title>
        <description>Participants were assessed for sneezing using the following score every 15 minutes from before cedar pollen exposure until 180 minutes after cedar pollen exposure. The mean of score at 120 to 180 minutes was calculated.
0: None (no symptoms)
Mild (symptoms present but easily tolerated)
Moderate (awareness of symptoms; bothersome, but tolerable)
Severe (definite awareness of symptoms; difficult to tolerate, but did not interfere with the activities of daily living)
Very severe (difficult to tolerate and interfered with the activities of daily living)</description>
        <time_frame>Pre-exposure and 120-180 minutes after the start of pollen exposure (5 samples 15 minutes apart) on Days 127, 155, and 183</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>ASP4070 4 mg</title>
            <description>Participants received ASP4070 4 mg 8 times by intradermal vaccination at 14-day intervals.</description>
          </group>
          <group group_id="O2">
            <title>ASP4070 1 mg</title>
            <description>Participants received ASP4070 1 mg 8 times by intradermal vaccination at 14-day intervals.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received Placebo 8 times by intradermal vaccination at 14-day intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Pre-Exposure in Sneezing Score 120 to 180 Minutes After Cedar Pollen Exposure</title>
          <description>Participants were assessed for sneezing using the following score every 15 minutes from before cedar pollen exposure until 180 minutes after cedar pollen exposure. The mean of score at 120 to 180 minutes was calculated.
0: None (no symptoms)
Mild (symptoms present but easily tolerated)
Moderate (awareness of symptoms; bothersome, but tolerable)
Severe (definite awareness of symptoms; difficult to tolerate, but did not interfere with the activities of daily living)
Very severe (difficult to tolerate and interfered with the activities of daily living)</description>
          <population>FAS</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 127</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.57" spread="0.57"/>
                    <measurement group_id="O2" value="0.47" spread="0.53"/>
                    <measurement group_id="O3" value="0.49" spread="0.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 155</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.46" spread="0.42"/>
                    <measurement group_id="O2" value="0.39" spread="0.37"/>
                    <measurement group_id="O3" value="0.39" spread="0.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 183</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.40" spread="0.41"/>
                    <measurement group_id="O2" value="0.28" spread="0.37"/>
                    <measurement group_id="O3" value="0.36" spread="0.32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Sneezing score treatment comparison at day 127</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.502</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.14</ci_lower_limit>
            <ci_upper_limit>0.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Sneezing score treatment comparison at day 127</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.879</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.02</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.23</ci_lower_limit>
            <ci_upper_limit>0.20</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Sneezing score treatment comparison at day 155</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.444</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.10</ci_lower_limit>
            <ci_upper_limit>0.22</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Sneezing score treatment comparison at day 155</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.987</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.16</ci_lower_limit>
            <ci_upper_limit>0.16</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Sneezing score treatment comparison at day 183</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.645</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.12</ci_lower_limit>
            <ci_upper_limit>0.18</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Sneezing score treatment comparison at day 183</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.357</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.22</ci_lower_limit>
            <ci_upper_limit>0.08</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Pre-Exposure in Nasal Discharge Score 120 to 180 Minutes After Cedar Pollen Exposure</title>
        <description>Participants were assessed for nasal discharge using the following score every 15 minutes from before cedar pollen exposure until 180 minutes after cedar pollen exposure. The mean of score at 120 to 180 minutes was calculated.
0: None (no symptoms)
Mild (symptoms present but easily tolerated)
Moderate (awareness of symptoms; bothersome, but tolerable)
Severe (definite awareness of symptoms; difficult to tolerate, but did not interfere with the activities of daily living)
Very severe (difficult to tolerate and interfered with the activities of daily living)</description>
        <time_frame>Pre-exposure and 120-180 minutes after the start of pollen exposure (5 samples 15 minutes apart) on Days 127, 155, and 183</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>ASP4070 4 mg</title>
            <description>Participants received ASP4070 4 mg 8 times by intradermal vaccination at 14-day intervals.</description>
          </group>
          <group group_id="O2">
            <title>ASP4070 1 mg</title>
            <description>Participants received ASP4070 1 mg 8 times by intradermal vaccination at 14-day intervals.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received Placebo 8 times by intradermal vaccination at 14-day intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Pre-Exposure in Nasal Discharge Score 120 to 180 Minutes After Cedar Pollen Exposure</title>
          <description>Participants were assessed for nasal discharge using the following score every 15 minutes from before cedar pollen exposure until 180 minutes after cedar pollen exposure. The mean of score at 120 to 180 minutes was calculated.
0: None (no symptoms)
Mild (symptoms present but easily tolerated)
Moderate (awareness of symptoms; bothersome, but tolerable)
Severe (definite awareness of symptoms; difficult to tolerate, but did not interfere with the activities of daily living)
Very severe (difficult to tolerate and interfered with the activities of daily living)</description>
          <population>FAS</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 127</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.54" spread="0.62"/>
                    <measurement group_id="O2" value="1.30" spread="0.93"/>
                    <measurement group_id="O3" value="1.42" spread="0.82"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 155</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.29" spread="0.69"/>
                    <measurement group_id="O2" value="1.12" spread="0.91"/>
                    <measurement group_id="O3" value="1.27" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 183</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.96" spread="0.65"/>
                    <measurement group_id="O2" value="0.93" spread="0.86"/>
                    <measurement group_id="O3" value="0.87" spread="0.62"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Nasal discharge score treatment comparison at day 127</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.472</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.20</ci_lower_limit>
            <ci_upper_limit>0.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Nasal discharge score treatment comparison at day 127</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.497</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.43</ci_lower_limit>
            <ci_upper_limit>0.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Nasal discharge score treatment comparison at day 155</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.821</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.28</ci_lower_limit>
            <ci_upper_limit>0.36</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Nasal discharge score treatment comparison at day 155</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.414</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.13</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.45</ci_lower_limit>
            <ci_upper_limit>0.19</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Nasal discharge score treatment comparison at day 183</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.414</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.17</ci_lower_limit>
            <ci_upper_limit>0.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Nasal discharge score treatment comparison at day 183</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.566</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.20</ci_lower_limit>
            <ci_upper_limit>0.37</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Pre-Exposure in Mean Nasal Congestion Score 120 to 180 Minutes After Cedar Pollen Exposure</title>
        <description>Participants were assessed for nasal congestion using the following score every 15 minutes from before cedar pollen exposure until 180 minutes after cedar pollen exposure. The mean of score at 120 to 180 minutes was calculated.
0: None (no symptoms)
Mild (symptoms present but easily tolerated)
Moderate (awareness of symptoms; bothersome, but tolerable)
Severe (definite awareness of symptoms; difficult to tolerate, but did not interfere with the activities of daily living)
Very severe (difficult to tolerate and interfered with the activities of daily living)</description>
        <time_frame>Pre-exposure and 120-180 minutes after the start of pollen exposure (5 samples 15 minutes apart) on Days 127, 155, and 183</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>ASP4070 4 mg</title>
            <description>Participants received ASP4070 4 mg 8 times by intradermal vaccination at 14-day intervals.</description>
          </group>
          <group group_id="O2">
            <title>ASP4070 1 mg</title>
            <description>Participants received ASP4070 1 mg 8 times by intradermal vaccination at 14-day intervals.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received Placebo 8 times by intradermal vaccination at 14-day intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Pre-Exposure in Mean Nasal Congestion Score 120 to 180 Minutes After Cedar Pollen Exposure</title>
          <description>Participants were assessed for nasal congestion using the following score every 15 minutes from before cedar pollen exposure until 180 minutes after cedar pollen exposure. The mean of score at 120 to 180 minutes was calculated.
0: None (no symptoms)
Mild (symptoms present but easily tolerated)
Moderate (awareness of symptoms; bothersome, but tolerable)
Severe (definite awareness of symptoms; difficult to tolerate, but did not interfere with the activities of daily living)
Very severe (difficult to tolerate and interfered with the activities of daily living)</description>
          <population>FAS</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 127</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.14" spread="0.70"/>
                    <measurement group_id="O2" value="1.26" spread="0.89"/>
                    <measurement group_id="O3" value="1.18" spread="0.92"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 155</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.91" spread="0.68"/>
                    <measurement group_id="O2" value="0.90" spread="0.89"/>
                    <measurement group_id="O3" value="0.92" spread="0.77"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 183</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68" spread="0.62"/>
                    <measurement group_id="O2" value="0.70" spread="0.78"/>
                    <measurement group_id="O3" value="0.75" spread="0.70"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Nasal congestion score treatment comparison at day 127</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.822</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.04</param_value>
            <ci_percent>95</ci_percent>
            <ci_lower_limit>-0.37</ci_lower_limit>
            <ci_upper_limit>0.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Nasal congestion score treatment comparison at day 127</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.587</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.09</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.24</ci_lower_limit>
            <ci_upper_limit>0.42</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Nasal congestion score treatment comparison at day 155</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.975</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.30</ci_lower_limit>
            <ci_upper_limit>0.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Nasal congestion score treatment comparison at day 155</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.980</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.00</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.31</ci_lower_limit>
            <ci_upper_limit>0.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Nasal congestion score treatment comparison at day 183</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.621</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.35</ci_lower_limit>
            <ci_upper_limit>0.21</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Nasal congestion score treatment comparison at day 183</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.831</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>-0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.31</ci_lower_limit>
            <ci_upper_limit>0.25</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Pre-Exposure in Mean Itchy Nose Score 120 to 180 Minutes After Cedar Pollen Exposure</title>
        <description>Participants were assessed for itchy nose using the following score every 15 minutes from before cedar pollen exposure until 180 minutes after cedar pollen exposure. The mean of score at 120 to 180 minutes was calculated.
0: None (no symptoms)
Mild (symptoms present but easily tolerated)
Moderate (awareness of symptoms; bothersome, but tolerable)
Severe (definite awareness of symptoms; difficult to tolerate, but did not interfere with the activities of daily living)
Very severe (difficult to tolerate and interfered with the activities of daily living)</description>
        <time_frame>Pre-exposure and 120-180 minutes after the start of pollen exposure (5 samples 15 minutes apart) on Days 127, 155, and 183</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>ASP4070 4 mg</title>
            <description>Participants received ASP4070 4 mg 8 times by intradermal vaccination at 14-day intervals.</description>
          </group>
          <group group_id="O2">
            <title>ASP4070 1 mg</title>
            <description>Participants received ASP4070 1 mg 8 times by intradermal vaccination at 14-day intervals.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received Placebo 8 times by intradermal vaccination at 14-day intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Pre-Exposure in Mean Itchy Nose Score 120 to 180 Minutes After Cedar Pollen Exposure</title>
          <description>Participants were assessed for itchy nose using the following score every 15 minutes from before cedar pollen exposure until 180 minutes after cedar pollen exposure. The mean of score at 120 to 180 minutes was calculated.
0: None (no symptoms)
Mild (symptoms present but easily tolerated)
Moderate (awareness of symptoms; bothersome, but tolerable)
Severe (definite awareness of symptoms; difficult to tolerate, but did not interfere with the activities of daily living)
Very severe (difficult to tolerate and interfered with the activities of daily living)</description>
          <population>FAS</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 127</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.97" spread="0.64"/>
                    <measurement group_id="O2" value="1.03" spread="0.88"/>
                    <measurement group_id="O3" value="0.93" spread="0.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 155</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.80" spread="0.75"/>
                    <measurement group_id="O2" value="0.79" spread="0.91"/>
                    <measurement group_id="O3" value="0.74" spread="0.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 183</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.68" spread="0.56"/>
                    <measurement group_id="O2" value="0.67" spread="0.80"/>
                    <measurement group_id="O3" value="0.63" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Itchy nose score treatment comparison at day 127</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.864</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.29</ci_lower_limit>
            <ci_upper_limit>0.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Itchy nose score treatment comparison at day 127</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.502</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.21</ci_lower_limit>
            <ci_upper_limit>0.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Itchy nose score treatment comparison at day 155</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.652</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.25</ci_lower_limit>
            <ci_upper_limit>0.40</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Itchy nose score treatment comparison at day 155</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.633</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.25</ci_lower_limit>
            <ci_upper_limit>0.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Itchy nose score treatment comparison at day 183</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.596</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.20</ci_lower_limit>
            <ci_upper_limit>0.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Itchy nose score treatment comparison at day 183</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.621</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.21</ci_lower_limit>
            <ci_upper_limit>0.34</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Pre-Exposure in Mean Total Non-Nasal Symptom Score (TNNSS) 120 to 180 Minutes After Cedar Pollen Exposure</title>
        <description>Participants were assessed for each non-nasal symptom (itchy eyes and watery eyes) using the following score every 15 minutes from before cedar pollen exposure until 180 minutes after cedar pollen exposure.
0: None (no symptoms)
Mild (symptoms present but easily tolerated)
Moderate (awareness of symptoms; bothersome, but tolerable)
Severe (definite awareness of symptoms; difficult to tolerate, but did not interfere with the activities of daily living)
Very severe (difficult to tolerate and interfered with the activities of daily living).
TNNSS was a summed score of each symptom, and mean of TNNSS at 120 to 180 min is the average of 5 timepoints of TNNSS score, which ranged from 0 to 8. Higher TNNSS score indicated greater disease activity.</description>
        <time_frame>Pre-exposure and 120-180 minutes after the start of pollen exposure (5 samples 15 minutes apart) on Days 127, 155, and 183</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>ASP4070 4 mg</title>
            <description>Participants received ASP4070 4 mg 8 times by intradermal vaccination at 14-day intervals.</description>
          </group>
          <group group_id="O2">
            <title>ASP4070 1 mg</title>
            <description>Participants received ASP4070 1 mg 8 times by intradermal vaccination at 14-day intervals.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received Placebo 8 times by intradermal vaccination at 14-day intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Pre-Exposure in Mean Total Non-Nasal Symptom Score (TNNSS) 120 to 180 Minutes After Cedar Pollen Exposure</title>
          <description>Participants were assessed for each non-nasal symptom (itchy eyes and watery eyes) using the following score every 15 minutes from before cedar pollen exposure until 180 minutes after cedar pollen exposure.
0: None (no symptoms)
Mild (symptoms present but easily tolerated)
Moderate (awareness of symptoms; bothersome, but tolerable)
Severe (definite awareness of symptoms; difficult to tolerate, but did not interfere with the activities of daily living)
Very severe (difficult to tolerate and interfered with the activities of daily living).
TNNSS was a summed score of each symptom, and mean of TNNSS at 120 to 180 min is the average of 5 timepoints of TNNSS score, which ranged from 0 to 8. Higher TNNSS score indicated greater disease activity.</description>
          <population>FAS</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 127</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.83" spread="1.22"/>
                    <measurement group_id="O2" value="0.96" spread="1.17"/>
                    <measurement group_id="O3" value="0.61" spread="0.93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 155</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.62" spread="1.10"/>
                    <measurement group_id="O2" value="0.83" spread="1.40"/>
                    <measurement group_id="O3" value="0.50" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 183</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.59" spread="1.09"/>
                    <measurement group_id="O2" value="0.73" spread="1.19"/>
                    <measurement group_id="O3" value="0.40" spread="0.71"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>TNNSS treatment comparison at day 127</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.336</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.22</ci_lower_limit>
            <ci_upper_limit>0.65</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>TNNSS treatment comparison at day 127</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.102</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.36</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.07</ci_lower_limit>
            <ci_upper_limit>0.80</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>TNNSS treatment comparison at day 155</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.625</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.11</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.34</ci_lower_limit>
            <ci_upper_limit>0.56</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>TNNSS treatment comparison at day 155</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.145</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.12</ci_lower_limit>
            <ci_upper_limit>0.78</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>TNNSS treatment comparison at day 183</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.364</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.19</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.22</ci_lower_limit>
            <ci_upper_limit>0.59</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>TNNSS treatment comparison at day 183</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.082</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.05</ci_lower_limit>
            <ci_upper_limit>0.76</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Pre-Exposure in Mean Itchy Eyes Score 120 to 180 Minutes After Cedar Pollen Exposure</title>
        <description>Participants were assessed for itchy eyes using the following score every 15 minutes from before cedar pollen exposure until 180 minutes after cedar pollen exposure. The mean of score at 120 to 180 minutes was calculated.
0: None (no symptoms)
Mild (symptoms present but easily tolerated)
Moderate (awareness of symptoms; bothersome, but tolerable)
Severe (definite awareness of symptoms; difficult to tolerate, but did not interfere with the activities of daily living)
Very severe (difficult to tolerate and interfered with the activities of daily living)</description>
        <time_frame>Pre-exposure and 120-180 minutes after the start of pollen exposure (5 samples 15 minutes apart) on Days 127, 155, and 183</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>ASP4070 4 mg</title>
            <description>Participants received ASP4070 4 mg 8 times by intradermal vaccination at 14-day intervals.</description>
          </group>
          <group group_id="O2">
            <title>ASP4070 1 mg</title>
            <description>Participants received ASP4070 1 mg 8 times by intradermal vaccination at 14-day intervals.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received Placebo 8 times by intradermal vaccination at 14-day intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Pre-Exposure in Mean Itchy Eyes Score 120 to 180 Minutes After Cedar Pollen Exposure</title>
          <description>Participants were assessed for itchy eyes using the following score every 15 minutes from before cedar pollen exposure until 180 minutes after cedar pollen exposure. The mean of score at 120 to 180 minutes was calculated.
0: None (no symptoms)
Mild (symptoms present but easily tolerated)
Moderate (awareness of symptoms; bothersome, but tolerable)
Severe (definite awareness of symptoms; difficult to tolerate, but did not interfere with the activities of daily living)
Very severe (difficult to tolerate and interfered with the activities of daily living)</description>
          <population>FAS</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 127</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.51" spread="0.75"/>
                    <measurement group_id="O2" value="0.58" spread="0.72"/>
                    <measurement group_id="O3" value="0.44" spread="0.66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 155</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.36" spread="0.63"/>
                    <measurement group_id="O2" value="0.49" spread="0.80"/>
                    <measurement group_id="O3" value="0.33" spread="0.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 183</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" spread="0.67"/>
                    <measurement group_id="O2" value="0.43" spread="0.69"/>
                    <measurement group_id="O3" value="0.29" spread="0.51"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Itchy eyes treatment comparison at day 127</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.623</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.07</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.21</ci_lower_limit>
            <ci_upper_limit>0.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Itchy eyes treatment comparison at day 127</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.288</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.13</ci_lower_limit>
            <ci_upper_limit>0.43</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Itchy eyes treatment comparison at day 155</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.830</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.03</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.24</ci_lower_limit>
            <ci_upper_limit>0.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Itchy eyes treatment comparison at day 155</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.208</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.17</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.10</ci_lower_limit>
            <ci_upper_limit>0.44</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Itchy eyes treatment comparison at day 183</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.616</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.19</ci_lower_limit>
            <ci_upper_limit>0.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Itchy eyes treatment comparison at day 183</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.207</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.09</ci_lower_limit>
            <ci_upper_limit>0.41</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Pre-Exposure in Mean Watery Eyes Score 120 to 180 Minutes After Cedar Pollen Exposure</title>
        <description>Participants were assessed for watery eyes using the following score every 15 minutes from before cedar pollen exposure until 180 minutes after cedar pollen exposure. The mean of score at 120 to 180 minutes was calculated.
0: None (no symptoms)
Mild (symptoms present but easily tolerated)
Moderate (awareness of symptoms; bothersome, but tolerable)
Severe (definite awareness of symptoms; difficult to tolerate, but did not interfere with the activities of daily living)
Very severe (difficult to tolerate and interfered with the activities of daily living)</description>
        <time_frame>Pre-exposure and 120-180 minutes after the start of pollen exposure (5 samples 15 minutes apart) on Days 127, 155, and 183</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>ASP4070 4 mg</title>
            <description>Participants received ASP4070 4 mg 8 times by intradermal vaccination at 14-day intervals.</description>
          </group>
          <group group_id="O2">
            <title>ASP4070 1 mg</title>
            <description>Participants received ASP4070 1 mg 8 times by intradermal vaccination at 14-day intervals.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received Placebo 8 times by intradermal vaccination at 14-day intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Pre-Exposure in Mean Watery Eyes Score 120 to 180 Minutes After Cedar Pollen Exposure</title>
          <description>Participants were assessed for watery eyes using the following score every 15 minutes from before cedar pollen exposure until 180 minutes after cedar pollen exposure. The mean of score at 120 to 180 minutes was calculated.
0: None (no symptoms)
Mild (symptoms present but easily tolerated)
Moderate (awareness of symptoms; bothersome, but tolerable)
Severe (definite awareness of symptoms; difficult to tolerate, but did not interfere with the activities of daily living)
Very severe (difficult to tolerate and interfered with the activities of daily living)</description>
          <population>FAS</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 127</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.32" spread="0.57"/>
                    <measurement group_id="O2" value="0.38" spread="0.57"/>
                    <measurement group_id="O3" value="0.17" spread="0.38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 155</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.26" spread="0.55"/>
                    <measurement group_id="O2" value="0.34" spread="0.67"/>
                    <measurement group_id="O3" value="0.17" spread="0.37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 183</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.24" spread="0.48"/>
                    <measurement group_id="O2" value="0.30" spread="0.57"/>
                    <measurement group_id="O3" value="0.11" spread="0.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Watery eyes treatment comparison at day 127</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.157</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.15</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.06</ci_lower_limit>
            <ci_upper_limit>0.35</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Watery eyes treatment comparison at day 127</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.039</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.01</ci_lower_limit>
            <ci_upper_limit>0.41</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Watery eyes treatment comparison at day 155</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.459</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.08</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.14</ci_lower_limit>
            <ci_upper_limit>0.30</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Watery eyes treatment comparison at day 155</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.153</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.16</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.06</ci_lower_limit>
            <ci_upper_limit>0.38</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Watery eyes treatment comparison at day 183</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.195</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.12</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.06</ci_lower_limit>
            <ci_upper_limit>0.31</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>Watery eyes treatment comparison at day 183</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.038</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.20</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.01</ci_lower_limit>
            <ci_upper_limit>0.38</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Pre-Exposure in Total 5 Symptom Score (5TSS) 120 to 180 Minutes After Cedar Pollen Exposure</title>
        <description>Participants were assessed for each 5TSS (sneezing, nasal discharge, nasal congestion, itchy eyes and watery eyes) using the following score every 15 minutes from before cedar pollen exposure until 180 minutes after cedar pollen exposure.
0: None (no symptoms)
Mild (symptoms present but easily tolerated)
Moderate (awareness of symptoms; bothersome, but tolerable)
Severe (definite awareness of symptoms; difficult to tolerate, but did not interfere with the activities of daily living)
Very severe (difficult to tolerate and interfered with the activities of daily living).
5TSS was a summed score of each symptom, and mean of 5TSS at 120 to 180 min is the average of 5 timepoints of 5TSS score, which ranged from 0 to 20. Higher 5TSS score indicated greater disease activity.</description>
        <time_frame>Pre-exposure and 120-180 minutes after the start of pollen exposure (5 samples 15 minutes apart) on Days 127, 155, and 183</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>ASP4070 4 mg</title>
            <description>Participants received ASP4070 4 mg 8 times by intradermal vaccination at 14-day intervals.</description>
          </group>
          <group group_id="O2">
            <title>ASP4070 1 mg</title>
            <description>Participants received ASP4070 1 mg 8 times by intradermal vaccination at 14-day intervals.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received Placebo 8 times by intradermal vaccination at 14-day intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Pre-Exposure in Total 5 Symptom Score (5TSS) 120 to 180 Minutes After Cedar Pollen Exposure</title>
          <description>Participants were assessed for each 5TSS (sneezing, nasal discharge, nasal congestion, itchy eyes and watery eyes) using the following score every 15 minutes from before cedar pollen exposure until 180 minutes after cedar pollen exposure.
0: None (no symptoms)
Mild (symptoms present but easily tolerated)
Moderate (awareness of symptoms; bothersome, but tolerable)
Severe (definite awareness of symptoms; difficult to tolerate, but did not interfere with the activities of daily living)
Very severe (difficult to tolerate and interfered with the activities of daily living).
5TSS was a summed score of each symptom, and mean of 5TSS at 120 to 180 min is the average of 5 timepoints of 5TSS score, which ranged from 0 to 20. Higher 5TSS score indicated greater disease activity.</description>
          <population>FAS</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 127</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.08" spread="1.95"/>
                    <measurement group_id="O2" value="3.99" spread="2.67"/>
                    <measurement group_id="O3" value="3.70" spread="2.40"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 155</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.28" spread="2.07"/>
                    <measurement group_id="O2" value="3.24" spread="2.98"/>
                    <measurement group_id="O3" value="3.07" spread="1.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 183</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.63" spread="1.82"/>
                    <measurement group_id="O2" value="2.64" spread="2.62"/>
                    <measurement group_id="O3" value="2.38" spread="1.68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>5TSS treatment comparison at day 127</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.433</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.37</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.56</ci_lower_limit>
            <ci_upper_limit>1.29</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>5TSS treatment comparison at day 127</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.479</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.33</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.59</ci_lower_limit>
            <ci_upper_limit>1.24</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>5TSS treatment comparison at day 155</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.648</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.71</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>5TSS treatment comparison at day 155</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.654</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.21</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.72</ci_lower_limit>
            <ci_upper_limit>1.14</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>5TSS treatment comparison at day 183</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.514</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.27</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.55</ci_lower_limit>
            <ci_upper_limit>1.09</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>5TSS treatment comparison at day 183</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.400</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference</param_type>
            <param_value>0.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.47</ci_lower_limit>
            <ci_upper_limit>1.17</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change From Pre-Exposure in Mean Total 6 Symptom Score (6TSS) 120 to 180 Minutes After Cedar Pollen Exposure</title>
        <description>Participants were assessed for each 6TSS (sneezing, nasal discharge, nasal congestion, itchy nose, itchy eyes and watery eyes) using the following score every 15 minutes from before cedar pollen exposure until 180 minutes after cedar pollen exposure.
0: None (no symptoms)
Mild (symptoms present but easily tolerated)
Moderate (awareness of symptoms; bothersome, but tolerable)
Severe (definite awareness of symptoms; difficult to tolerate, but did not interfere with the activities of daily living)
Very severe (difficult to tolerate and interfered with the activities of daily living).
6TSS was a summed score of each symptom, and mean of 6TSS at 120 to 180 min is the average of 5 timepoints of 6TSS score, which ranged from 0 to 24. Higher 6TSS score indicated greater disease activity.</description>
        <time_frame>Pre-exposure and 120-180 minutes after the start of pollen exposure (5 samples 15 minutes apart) on Days 127, 155, and 183</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>ASP4070 4 mg</title>
            <description>Participants received ASP4070 4 mg 8 times by intradermal vaccination at 14-day intervals.</description>
          </group>
          <group group_id="O2">
            <title>ASP4070 1 mg</title>
            <description>Participants received ASP4070 1 mg 8 times by intradermal vaccination at 14-day intervals.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received Placebo 8 times by intradermal vaccination at 14-day intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Change From Pre-Exposure in Mean Total 6 Symptom Score (6TSS) 120 to 180 Minutes After Cedar Pollen Exposure</title>
          <description>Participants were assessed for each 6TSS (sneezing, nasal discharge, nasal congestion, itchy nose, itchy eyes and watery eyes) using the following score every 15 minutes from before cedar pollen exposure until 180 minutes after cedar pollen exposure.
0: None (no symptoms)
Mild (symptoms present but easily tolerated)
Moderate (awareness of symptoms; bothersome, but tolerable)
Severe (definite awareness of symptoms; difficult to tolerate, but did not interfere with the activities of daily living)
Very severe (difficult to tolerate and interfered with the activities of daily living).
6TSS was a summed score of each symptom, and mean of 6TSS at 120 to 180 min is the average of 5 timepoints of 6TSS score, which ranged from 0 to 24. Higher 6TSS score indicated greater disease activity.</description>
          <population>FAS</population>
          <units>units on a scale</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 127</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.04" spread="2.39"/>
                    <measurement group_id="O2" value="5.02" spread="3.31"/>
                    <measurement group_id="O3" value="4.63" spread="3.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 155</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.08" spread="2.66"/>
                    <measurement group_id="O2" value="4.03" spread="3.74"/>
                    <measurement group_id="O3" value="3.82" spread="2.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 183</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.30" spread="2.19"/>
                    <measurement group_id="O2" value="3.31" spread="3.29"/>
                    <measurement group_id="O3" value="3.02" spread="2.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>6TSS treatment comparison at day 127</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.505</p_value>
            <p_value_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</p_value_desc>
            <method>MMRM</method>
            <param_type>Adjusted mean difference,</param_type>
            <param_value>0.39</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.76</ci_lower_limit>
            <ci_upper_limit>1.54</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>6TSS treatment comparison at day 127</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.451</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference,</param_type>
            <param_value>0.44</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.71</ci_lower_limit>
            <ci_upper_limit>1.58</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>6TSS treatment comparison at day 155</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.623</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference,</param_type>
            <param_value>0.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.88</ci_lower_limit>
            <ci_upper_limit>1.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>6TSS treatment comparison at day 155</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.620</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference,</param_type>
            <param_value>0.29</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.87</ci_lower_limit>
            <ci_upper_limit>1.46</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>6TSS treatment comparison at day 183</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.504</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference,</param_type>
            <param_value>0.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.68</ci_lower_limit>
            <ci_upper_limit>1.37</ci_upper_limit>
          </analysis>
          <analysis>
            <group_id_list>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
            </group_id_list>
            <groups_desc>6TSS treatment comparison at day 183</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.414</p_value>
            <method>MMRM</method>
            <method_desc>The MMRM model included treatment group, stratification factors, analysis visit and interaction of treatment group and analysis visit.</method_desc>
            <param_type>Adjusted mean difference,</param_type>
            <param_value>0.42</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.60</ci_lower_limit>
            <ci_upper_limit>1.45</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Occurrence of Nasal or Eye Symptom From Start of Cedar Pollen Exposure</title>
        <description>Time point when the score of nasal or eye symptom worsens by 1 or more as compared to before cedar pollen exposure were assessed.</description>
        <time_frame>Days 127, 155 and 183, from the start of cedar pollen exposure for up to 180 minutes</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>ASP4070 4 mg</title>
            <description>Participants received ASP4070 4 mg 8 times by intradermal vaccination at 14-day intervals.</description>
          </group>
          <group group_id="O2">
            <title>ASP4070 1 mg</title>
            <description>Participants received ASP4070 1 mg 8 times by intradermal vaccination at 14-day intervals.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received Placebo 8 times by intradermal vaccination at 14-day intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Time to Occurrence of Nasal or Eye Symptom From Start of Cedar Pollen Exposure</title>
          <description>Time point when the score of nasal or eye symptom worsens by 1 or more as compared to before cedar pollen exposure were assessed.</description>
          <population>FAS</population>
          <units>minutes</units>
          <param>Median</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 127</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="15.0" lower_limit="15.0" upper_limit="30.0"/>
                    <measurement group_id="O2" value="15.0" lower_limit="15.0" upper_limit="30.0"/>
                    <measurement group_id="O3" value="30.0" lower_limit="15.0" upper_limit="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 155</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="44"/>
                    <count group_id="O3" value="45"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22.5" lower_limit="15.0" upper_limit="30.0"/>
                    <measurement group_id="O2" value="30.0" lower_limit="15.0" upper_limit="30.0"/>
                    <measurement group_id="O3" value="15.0" lower_limit="15.0" upper_limit="30.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 183</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="43"/>
                    <count group_id="O3" value="44"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="30.0" lower_limit="NA" upper_limit="NA">95% Confidential Interval (CI) was not technically defined due to insufficient number of participants with events around the percentile.</measurement>
                    <measurement group_id="O2" value="30.0" lower_limit="15.0" upper_limit="45.0"/>
                    <measurement group_id="O3" value="30.0" lower_limit="NA" upper_limit="NA">95% Confidential Interval (CI) was not technically defined due to insufficient number of participants with events around the percentile.</measurement>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Amount of Nasal Discharge Per 30 Minutes During Cedar Pollen Exposure</title>
        <description>Nasal discharge amount was calculated by the difference in the weight of the tissue paper before and after use by participants who were instructed to use pre-allocated tissues for blowing their nose.</description>
        <time_frame>Day 127: 0-30 min, 30-60 min, 60-90 min, 90-120 min, 120-150 min, 150-180 min, Day 155: 0-30 min, 30-60 min, 60-90 min, 90-120 min, 120-150 min, 150-180 min, Day 183: 0-30 min, 30-60 min, 60-90 min, 90-120 min, 120-150 min, 150-180 min</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>ASP4070 4 mg</title>
            <description>Participants received ASP4070 4 mg 8 times by intradermal vaccination at 14-day intervals.</description>
          </group>
          <group group_id="O2">
            <title>ASP4070 1 mg</title>
            <description>Participants received ASP4070 1 mg 8 times by intradermal vaccination at 14-day intervals.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received Placebo 8 times by intradermal vaccination at 14-day intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Amount of Nasal Discharge Per 30 Minutes During Cedar Pollen Exposure</title>
          <description>Nasal discharge amount was calculated by the difference in the weight of the tissue paper before and after use by participants who were instructed to use pre-allocated tissues for blowing their nose.</description>
          <population>FAS</population>
          <units>gram</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 127: 0-30 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.57" spread="0.90"/>
                    <measurement group_id="O2" value="0.80" spread="1.31"/>
                    <measurement group_id="O3" value="0.68" spread="1.11"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 127: 30-60 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.21" spread="1.06"/>
                    <measurement group_id="O2" value="1.35" spread="1.74"/>
                    <measurement group_id="O3" value="1.43" spread="1.58"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 127: 60-90 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.58" spread="1.41"/>
                    <measurement group_id="O2" value="1.61" spread="1.91"/>
                    <measurement group_id="O3" value="1.73" spread="1.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 127: 90-120 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.72" spread="1.53"/>
                    <measurement group_id="O2" value="1.43" spread="1.76"/>
                    <measurement group_id="O3" value="1.67" spread="2.24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 127: 120-150 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.49" spread="1.28"/>
                    <measurement group_id="O2" value="1.59" spread="1.96"/>
                    <measurement group_id="O3" value="1.67" spread="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 127: 150-180 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.64" spread="1.42"/>
                    <measurement group_id="O2" value="1.56" spread="1.77"/>
                    <measurement group_id="O3" value="1.61" spread="1.79"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 155: 0-30 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.55" spread="1.88"/>
                    <measurement group_id="O2" value="0.79" spread="1.66"/>
                    <measurement group_id="O3" value="0.91" spread="1.52"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 155: 30-60 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.12" spread="1.31"/>
                    <measurement group_id="O2" value="1.23" spread="1.72"/>
                    <measurement group_id="O3" value="1.57" spread="1.64"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 155: 60-90 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.25" spread="1.46"/>
                    <measurement group_id="O2" value="1.45" spread="2.08"/>
                    <measurement group_id="O3" value="1.75" spread="1.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 155: 90-120 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.42" spread="1.79"/>
                    <measurement group_id="O2" value="1.62" spread="2.24"/>
                    <measurement group_id="O3" value="1.71" spread="1.89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 155: 120-150 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.45" spread="1.57"/>
                    <measurement group_id="O2" value="1.82" spread="2.59"/>
                    <measurement group_id="O3" value="1.83" spread="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 155: 150-180 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.63" spread="1.69"/>
                    <measurement group_id="O2" value="1.91" spread="2.56"/>
                    <measurement group_id="O3" value="1.70" spread="2.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 183: 0-30 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.35" spread="0.92"/>
                    <measurement group_id="O2" value="0.44" spread="0.89"/>
                    <measurement group_id="O3" value="0.49" spread="1.16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 183: 30-60 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.57" spread="1.00"/>
                    <measurement group_id="O2" value="0.73" spread="1.08"/>
                    <measurement group_id="O3" value="0.90" spread="1.39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 183: 60-90 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.71" spread="0.94"/>
                    <measurement group_id="O2" value="1.20" spread="1.93"/>
                    <measurement group_id="O3" value="0.84" spread="0.98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 183: 90-120 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.94" spread="1.23"/>
                    <measurement group_id="O2" value="1.23" spread="2.02"/>
                    <measurement group_id="O3" value="0.90" spread="1.02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 183: 120-150 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.13" spread="1.52"/>
                    <measurement group_id="O2" value="1.42" spread="2.18"/>
                    <measurement group_id="O3" value="1.05" spread="1.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 183: 150-180 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.06" spread="1.35"/>
                    <measurement group_id="O2" value="1.54" spread="2.07"/>
                    <measurement group_id="O3" value="1.23" spread="1.34"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Sneezing Count Per 30 Minutes During Cedar Pollen Exposure</title>
        <description>Sneezing count per 30 minutes were measured during chamber exposure.</description>
        <time_frame>Day 127: 0-30 min, 30-60 min, 60-90 min, 90-120 min, 120-150 min, 150-180 min, Day 155: 0-30 min, 30-60 min, 60-90 min, 90-120 min, 120-150 min, 150-180 min, Day 183: 0-30 min, 30-60 min, 60-90 min, 90-120 min, 120-150 min, 150-180 min</time_frame>
        <population>FAS</population>
        <group_list>
          <group group_id="O1">
            <title>ASP4070 4 mg</title>
            <description>Participants received ASP4070 4 mg 8 times by intradermal vaccination at 14-day intervals.</description>
          </group>
          <group group_id="O2">
            <title>ASP4070 1 mg</title>
            <description>Participants received ASP4070 1 mg 8 times by intradermal vaccination at 14-day intervals.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received Placebo 8 times by intradermal vaccination at 14-day intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Sneezing Count Per 30 Minutes During Cedar Pollen Exposure</title>
          <description>Sneezing count per 30 minutes were measured during chamber exposure.</description>
          <population>FAS</population>
          <units>sneezes</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="48"/>
                <count group_id="O2" value="49"/>
                <count group_id="O3" value="48"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Day 127: 0-30 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.4" spread="0.7"/>
                    <measurement group_id="O2" value="0.8" spread="0.9"/>
                    <measurement group_id="O3" value="1.1" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 127: 30-60 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="1.2"/>
                    <measurement group_id="O2" value="1.0" spread="1.5"/>
                    <measurement group_id="O3" value="1.3" spread="2.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 127: 60-90 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="2.0"/>
                    <measurement group_id="O2" value="1.5" spread="2.0"/>
                    <measurement group_id="O3" value="1.3" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 127: 90-120 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="1.9"/>
                    <measurement group_id="O2" value="1.2" spread="2.4"/>
                    <measurement group_id="O3" value="1.7" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 127: 120-150 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.5" spread="2.6"/>
                    <measurement group_id="O2" value="1.4" spread="2.1"/>
                    <measurement group_id="O3" value="1.3" spread="2.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 127: 150-180 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="49"/>
                    <count group_id="O3" value="48"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.6" spread="2.1"/>
                    <measurement group_id="O2" value="1.2" spread="1.7"/>
                    <measurement group_id="O3" value="1.5" spread="2.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 155: 0-30 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="1.1"/>
                    <measurement group_id="O2" value="0.6" spread="0.8"/>
                    <measurement group_id="O3" value="0.8" spread="1.4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 155: 30-60 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="1.2"/>
                    <measurement group_id="O2" value="1.0" spread="1.4"/>
                    <measurement group_id="O3" value="1.1" spread="2.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 155: 60-90 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="48"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="1.1"/>
                    <measurement group_id="O2" value="1.1" spread="1.4"/>
                    <measurement group_id="O3" value="1.1" spread="1.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 155: 90-120 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="1.8"/>
                    <measurement group_id="O2" value="1.1" spread="1.9"/>
                    <measurement group_id="O3" value="1.0" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 155: 120-150 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="1.3"/>
                    <measurement group_id="O2" value="1.0" spread="1.3"/>
                    <measurement group_id="O3" value="1.3" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 155: 150-180 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="47"/>
                    <count group_id="O3" value="46"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.4" spread="2.0"/>
                    <measurement group_id="O2" value="1.0" spread="1.4"/>
                    <measurement group_id="O3" value="1.0" spread="1.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 183: 0-30 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.6" spread="1.0"/>
                    <measurement group_id="O2" value="0.6" spread="1.0"/>
                    <measurement group_id="O3" value="0.5" spread="0.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 183: 30-60 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.7" spread="1.3"/>
                    <measurement group_id="O2" value="0.4" spread="0.8"/>
                    <measurement group_id="O3" value="0.6" spread="0.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 183: 60-90 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.8" spread="0.9"/>
                    <measurement group_id="O2" value="0.7" spread="1.0"/>
                    <measurement group_id="O3" value="0.9" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 183: 90-120 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.0" spread="1.3"/>
                    <measurement group_id="O2" value="0.7" spread="1.1"/>
                    <measurement group_id="O3" value="0.9" spread="1.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 183: 120-150 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.1" spread="1.5"/>
                    <measurement group_id="O2" value="0.7" spread="1.0"/>
                    <measurement group_id="O3" value="1.1" spread="1.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Day 183: 150-180 min</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="47"/>
                    <count group_id="O2" value="48"/>
                    <count group_id="O3" value="47"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.9" spread="1.4"/>
                    <measurement group_id="O2" value="0.8" spread="1.3"/>
                    <measurement group_id="O3" value="1.0" spread="1.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Adverse Events (AE) During the Primary Study Period</title>
        <description>Treatment emergent adverse events (TEAE) was defined as an AE observed after starting administration of the test drug/comparative drug. A drug-related TEAE was a TEAE with either possible or probable relationship to the study drug as assessed by the investigator. Severity of AEs was assessed according to the following 4 levels. Mild: no disruption of normal daily activities, Moderate: affect normal daily activities, Severe: inability to perform daily activities, Life-threatening: necessity for urgent intervention.
If the investigator or subinvestigator examined the patient and determined that the following items occurred from the date of study drug vaccination until 14 days after vaccination and a relationship with the study drug could not be negated, then it was evaluated as a local/systemic reaction at the vaccination site.
Local reactions: pain, tenderness, erythema/redness and induration/swelling
Systemic reactions: nausea/vomiting, diarrhea, headache, fatigue and myalgia</description>
        <time_frame>From first dose of study drug up to the end of primary study period (up to 7 days after Day 183)</time_frame>
        <population>SAF</population>
        <group_list>
          <group group_id="O1">
            <title>ASP4070 4 mg</title>
            <description>Participants received ASP4070 4 mg 8 times by intradermal vaccination at 14-day intervals.</description>
          </group>
          <group group_id="O2">
            <title>ASP4070 1 mg</title>
            <description>Participants received ASP4070 1 mg 8 times by intradermal vaccination at 14-day intervals.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received Placebo 8 times by intradermal vaccination at 14-day intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Adverse Events (AE) During the Primary Study Period</title>
          <description>Treatment emergent adverse events (TEAE) was defined as an AE observed after starting administration of the test drug/comparative drug. A drug-related TEAE was a TEAE with either possible or probable relationship to the study drug as assessed by the investigator. Severity of AEs was assessed according to the following 4 levels. Mild: no disruption of normal daily activities, Moderate: affect normal daily activities, Severe: inability to perform daily activities, Life-threatening: necessity for urgent intervention.
If the investigator or subinvestigator examined the patient and determined that the following items occurred from the date of study drug vaccination until 14 days after vaccination and a relationship with the study drug could not be negated, then it was evaluated as a local/systemic reaction at the vaccination site.
Local reactions: pain, tenderness, erythema/redness and induration/swelling
Systemic reactions: nausea/vomiting, diarrhea, headache, fatigue and myalgia</description>
          <population>SAF</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="49"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="28"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Mild</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="33"/>
                    <measurement group_id="O2" value="33"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Moderate</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="11"/>
                    <measurement group_id="O3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Severe</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Life-threatening Possibility</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-related TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="45"/>
                    <measurement group_id="O2" value="37"/>
                    <measurement group_id="O3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Device-Related TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-related serious TEAE</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAE leading to withdrawal of treatment</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-related TEAE leading to withdrawal of treat.</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Death</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Local reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="34"/>
                    <measurement group_id="O2" value="24"/>
                    <measurement group_id="O3" value="7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Systemic reaction</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13"/>
                    <measurement group_id="O2" value="13"/>
                    <measurement group_id="O3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>TEAEs other than local or systemic reactions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="40"/>
                    <measurement group_id="O3" value="21"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Drug-related TEAEs other than local or systemic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="38"/>
                    <measurement group_id="O2" value="31"/>
                    <measurement group_id="O3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With Serious Adverse Events (SAE) During the Long-Term Safety Follow-Up Period</title>
        <description>If SAEs occurred, then the participant was to contact the study site. With regard to participants who had discontinued the study during the primary study period, if the study drug had been vaccinated even once, then safety information (SAEs) was collected for 1 year after the final vaccination.</description>
        <time_frame>Up to 9 months after the end of primary study period (primary study period was up to 7 days after Day 183)</time_frame>
        <population>SAF</population>
        <group_list>
          <group group_id="O1">
            <title>ASP4070 4 mg</title>
            <description>Participants received ASP4070 4 mg 8 times by intradermal vaccination at 14-day intervals.</description>
          </group>
          <group group_id="O2">
            <title>ASP4070 1 mg</title>
            <description>Participants received ASP4070 1 mg 8 times by intradermal vaccination at 14-day intervals.</description>
          </group>
          <group group_id="O3">
            <title>Placebo</title>
            <description>Participants received Placebo 8 times by intradermal vaccination at 14-day intervals.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Serious Adverse Events (SAE) During the Long-Term Safety Follow-Up Period</title>
          <description>If SAEs occurred, then the participant was to contact the study site. With regard to participants who had discontinued the study during the primary study period, if the study drug had been vaccinated even once, then safety information (SAEs) was collected for 1 year after the final vaccination.</description>
          <population>SAF</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="0"/>
                    <measurement group_id="O3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From first dose of study drug up to the end of primary study period (up to 7 days after Day 183). SAEs were collected up to 9 months after the end of primary study period (until 12 months after the final vaccination of the study drug).</time_frame>
      <desc>SAF consisted of all participants who were vaccinated with the study drug at least once.</desc>
      <group_list>
        <group group_id="E1">
          <title>ASP4070 4 mg</title>
          <description>Participants received ASP4070 4 mg 8 times by intradermal vaccination at 14-day intervals.</description>
        </group>
        <group group_id="E2">
          <title>ASP4070 1 mg</title>
          <description>Participants received ASP4070 1 mg 8 times by intradermal vaccination at 14-day intervals.</description>
        </group>
        <group group_id="E3">
          <title>Placebo</title>
          <description>Participants received Placebo 8 times by intradermal vaccination at 14-day intervals.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Appendiceal abscess</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Appendicitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA 19.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="47" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="41" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="23" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" events="13" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E2" events="19" subjects_affected="6" subjects_at_risk="50"/>
                <counts group_id="E3" events="8" subjects_affected="7" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Induration</sub_title>
                <counts group_id="E1" events="24" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E2" events="6" subjects_affected="2" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Pain</sub_title>
                <counts group_id="E1" events="32" subjects_affected="11" subjects_at_risk="50"/>
                <counts group_id="E2" events="10" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Swelling</sub_title>
                <counts group_id="E1" events="14" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Tenderness</sub_title>
                <counts group_id="E1" events="71" subjects_affected="23" subjects_at_risk="50"/>
                <counts group_id="E2" events="62" subjects_affected="13" subjects_at_risk="50"/>
                <counts group_id="E3" events="6" subjects_affected="5" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Vaccination site pruritus</sub_title>
                <counts group_id="E1" events="179" subjects_affected="37" subjects_at_risk="50"/>
                <counts group_id="E2" events="134" subjects_affected="29" subjects_at_risk="50"/>
                <counts group_id="E3" events="0" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" events="19" subjects_affected="18" subjects_at_risk="50"/>
                <counts group_id="E2" events="12" subjects_affected="11" subjects_at_risk="50"/>
                <counts group_id="E3" events="13" subjects_affected="9" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Myalgia</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="50"/>
                <counts group_id="E2" events="4" subjects_affected="4" subjects_at_risk="50"/>
                <counts group_id="E3" events="4" subjects_affected="4" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="13" subjects_affected="8" subjects_at_risk="50"/>
                <counts group_id="E2" events="27" subjects_affected="14" subjects_at_risk="50"/>
                <counts group_id="E3" events="5" subjects_affected="4" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Rhinorrhoea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" events="5" subjects_affected="5" subjects_at_risk="50"/>
                <counts group_id="E3" events="2" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Erythema</sub_title>
                <counts group_id="E1" events="146" subjects_affected="31" subjects_at_risk="50"/>
                <counts group_id="E2" events="43" subjects_affected="15" subjects_at_risk="50"/>
                <counts group_id="E3" events="7" subjects_affected="2" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>Institute and/or Principal Investigator may publish trial data generated at their specific study site after Sponsor publication of the multi-center data. Sponsor must receive a site's manuscript prior to publication for review and comment as specified in the Investigator Agreement.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Clinical Trial Disclosure</name_or_title>
      <organization>Astellas Pharma Inc.</organization>
      <phone>+81-3-3244-6500 Japanese only</phone>
      <email>astellas.resultsdisclosure@astellas.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

